Company Description
Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications.
The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.
The company was founded in 2001 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 50 |
| CEO | Stephen Yoder |
Contact Details
Address: 225 Franklin Street, 26th Floor Boston, Massachusetts 02110 United States | |
| Phone | 857 246 8998 |
| Website | pieris.com |
Stock Details
| Ticker Symbol | PIRS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001583648 |
| CUSIP Number | 720795103 |
| ISIN Number | US7207951036 |
| Employer ID | 30-0784346 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Stephen S. Yoder J.D. | Chief Executive Officer, President and Director |
| Maria Kelman | Executive Director of Investor Relations |
| Prompong Chaikul | Chief Supply Chain Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 8, 2024 | EFFECT | Notice of Effectiveness |
| Nov 8, 2024 | 424B3 | Prospectus |
| Nov 7, 2024 | 425 | Filing |
| Nov 7, 2024 | S-4/A | Filing |
| Nov 6, 2024 | DEF 14A | Other definitive proxy statements |
| Nov 6, 2024 | ARS | Filing |
| Nov 5, 2024 | S-4/A | Filing |
| Oct 29, 2024 | S-4/A | Filing |